Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients
Xingjuan Zhao,Xuan Yang,Lei Fu,Keda Yu
DOI: https://doi.org/10.2147/CMAR.S276422
2021-06-10
Cancer Management and Research
Abstract:Xingjuan Zhao, 1 Xuan Yang, 1 Lei Fu, 2 Keda Yu 3 1 Department of Mammary Gland, Shanxi People's Hospital, Taiyuan City, Shanxi Province, 030000, People's Republic of China; 2 Department of Surgery, Shanxi Provincial General Team Hospital of the Chinese People's Armed Police Force, Taiyuan City, Shanxi Province, 030000, People's Republic of China; 3 Department of Mammary Gland, Fudan University Cancer Hospital, Taiyuan City, Shanxi Province, 030000, People's Republic of China Correspondence: Xingjuan Zhao Department of Mammary Gland, Shanxi People's Hospital, No. 29 Shuangtasi Street, Taiyuan City, Shanxi Province, 030000, People's Republic of China Email Objective: The functions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 in breast cancer have been explored. This study was carried out to explore ER, PR, HER-2 and Ki-67 expression levels in breast cancer patients and their relationship with ultrasound signs and prognosis. Patients and Methods: A total of 274 female primary breast cancer patients received preoperative ultrasound examination. ER, PR, HER-2 and Ki-67 expression levels in breast cancer tissues were detected by immunohistochemical staining after surgery. The correlations of ER, PR, HER-2 and Ki-67 expression with ultrasound signs and prognosis of breast cancer patients were analyzed. Results: The positive expression rate of ER, PR and HER-2 and Ki-67 high expression in 274 breast cancer patients was 73.36% (201/274), 59.85% (164/274), 24.09% (66/274) and 66.06% (181/274), respectively. ER-positive expression had association with lymph node metastasis (LNM) and blood flow grading; HER-2-positive expression was associated with LNM, while Ki-67-positive expression was related to the tumor diameter, LNM, and blood flow grading. LNM and Ki-67 high expression were risk factors for OS; PR-positive was a protective factor for OS; TNM stage, tumor diameter, LNM and Ki-67 high expression were risk factors for DFS in breast cancer patients. Conclusion: ER, PR, HER-2 and Ki-67 in breast cancer are related to the ultrasound signs and prognosis of breast cancer patients. The joint detection of multiple indicators provides a reference for the individualized treatment of targeted drugs. Keywords: estrogen receptor, progesterone receptor, human epidemic growth factor receptor-2, Ki-67, breast cancer, ultrasound signs, prognosis Breast cancer is a complicated disease that has the characteristics of molecular and genetic diversity, contributing to the identification of several fundamentally varying subtypes. 1 The morbidity of breast cancer has been increasingly elevated and is now regarded a commonly seen cancer among Chinese women. 2 Breast cancer initiation and progression are caused by different endogenous or exogenous reasons, including genetics, endocrine level, environment as well as lifestyle/habitat. 3 Evidence has shown that breast lumps, skin changes, enlarged axillary lymph nodes, non-gestational nipple discharge as well as nipple and/or areola abnormalities are the main clinical symptoms of breast cancer. 4 Surgery, chemotherapy, immunotherapy, endocrine therapy, and targeted therapy are the comprehensive treatments for breast cancer. 5 However, breast cancer survivors are still confronted with risks of locoregional recurrence irrespective of different treatments, 6 which make the recognition of effective biomarkers in breast cancer diagnosis more important. Nowadays, the molecular diagnostic technique has drawn some research interests due to its benefit in the diagnostic and prognostic assessment of breast cancer. 7 Breast cancer is traditionally assorted in the light of the presence of the steroid hormones, the receptors (estrogen receptor (ER), progesterone receptor (PR), human epidemic growth factor receptor-2 (HER2), as well as proliferation index Ki-67. 5 Currently, the immunohistochemistry-based molecular classification is suggested to have a close relationship with breast cancer prognosis, which is considered as a standard regimen for selecting the most useful approaches in breast cancer patient. 8 For breast cancer, the ER and PR are the initial predictive molecular biomarkers. Breast cancer patients who have positive ER and PR generally possess high sensitivity to hormone therapy. 9 HER2 gene is an oncogene in epidermal growth factor receptor -Abstract Truncated-
oncology